Sandoz’ Neulasta Biosimilar Filing Joins Another Pending At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Novartis drug unit said the biosimilar pegfilgrastim application was accepted by FDA, positioning the 351(k) filing for action in mid-2016.
You may also be interested in...
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.